The expected event-free survival for patients undergoing high-dose salvage
therapy for Hodgkin's disease is 40%-60%. Three-quarters of these patients
will relapse in prior sites of disease. Radiation therapy is a very effecti
ve local-regional modality in Hodgkin's disease. It is possible that the ju
dicious use of radiation can improve the event-free survival of high-dose s
alvage programs. Retrospective analysis supports this concept, but the rati
onale should be incorporated and tested in prospective clinical trials.